LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Начало・Списък с акции・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Затворен

СекторЗдравеопазване

20.4 1.69

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

19.5

Максимум

20.55

Ключови измерители
By Trading Economics
Приходи	-5M -47M
Продажби	-480K 695K
EPS	-0.81
Марж на печалбата	-4,007.83
Служители	186
EBITDA	-3.9M -55M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+197.41% upside

Дивиденти
By Dow Jones
Следващи печалби	6.08.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-7.3M 1.3B
Предишно отваряне	18.71
Предишно затваряне	20.4

Настроения в новините

By Acuity

50%

173 / 382 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bullish Evidence

18.91 / 20.63 Подкрепа & съпротива

Celldex Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

16.05.2025 г., 19:39 ч. UTC

Значими двигатели на пазара

UroGen Falls to 52-Week Low, FDA Document Indicates Cancer Drug Study Disagreement

16.05.2025 г., 23:18 ч. UTC

Топ новини

U.S. Loses Last Triple-A Credit Rating -- 2nd Update

16.05.2025 г., 22:30 ч. UTC

Топ новини

U.S. Loses Last Triple-A Credit Rating -- Update

16.05.2025 г., 21:56 ч. UTC

Пазарно говорене

Fitch Raises Greece's Outlook to Positive From Stable -- Market Talk

16.05.2025 г., 21:56 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

16.05.2025 г., 21:54 ч. UTC

Топ новини

U.S. Loses Last Triple-A Credit Rating -- WSJ

16.05.2025 г., 21:22 ч. UTC

Пазарно говорене

Moody's Says U.S. Fiscal Performance Likely to Deteriorate -- Market Talk

16.05.2025 г., 21:17 ч. UTC

Пазарно говорене

Treasury Yields Rise, Dollar Falls After Moody's Cuts U.S. Credit Rating -- Market Talk

16.05.2025 г., 21:17 ч. UTC

Топ новини

The Score: UnitedHealth, Walmart, Coinbase Global and More Stocks That Moved on the Week's News -- WSJ

16.05.2025 г., 21:05 ч. UTC

Пазарно говорене

Moody's Downgrades U.S. Credit Rating Due to Deficit, Debts -- Market Talk

16.05.2025 г., 20:55 ч. UTC

Придобивния, сливания и поглъщания

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16.05.2025 г., 20:50 ч. UTC

Пазарно говорене

Печалби

Financial Services Roundup: Market Talk

16.05.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

16.05.2025 г., 20:37 ч. UTC

Топ новини

Trade Progress Sparks Bullish Week for Wall Street -- WSJ

16.05.2025 г., 20:33 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Dick's-Foot Locker Deal Looks Like a Bet on Nike's Turnaround -- Market Talk

16.05.2025 г., 20:30 ч. UTC

Придобивния, сливания и поглъщания

Galaxy Digital Begins U.S. Trading as Bitcoin Keeps Powering Ahead -- Barrons.com

16.05.2025 г., 20:18 ч. UTC

Топ новини

Major U.S. Stock Indexes Rise; U.S. Running Out of Patience for Trade Deals -- WSJ

16.05.2025 г., 20:16 ч. UTC

Топ новини

Justice Department Wants to Spare Boeing From Guilty Plea Over 737 MAX Charges -- 3rd Update

16.05.2025 г., 20:15 ч. UTC

Печалби

Tesla Stock Rises. Even Hedge Fund Sales Can't Keep It Down. -- Barrons.com

16.05.2025 г., 20:11 ч. UTC

Придобивния, сливания и поглъщания

Henry Schein: William K. Daniel Joins Board

16.05.2025 г., 20:10 ч. UTC

Придобивния, сливания и поглъщания

Henry Schein: Strategic Investment by KKR Completed

16.05.2025 г., 20:05 ч. UTC

Придобивния, сливания и поглъщания

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16.05.2025 г., 19:38 ч. UTC

Пазарно говорене

Oil Futures Post Second Straight Weekly Gain -- Market Talk

16.05.2025 г., 19:07 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures End Week Lower -- Market Talk

16.05.2025 г., 18:51 ч. UTC

Топ новини

Early Read on Consumer Sentiment Falls to Second Lowest on Record -- 5th Update

16.05.2025 г., 18:41 ч. UTC

Придобивния, сливания и поглъщания

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16.05.2025 г., 18:37 ч. UTC

Пазарно говорене

Gold Futures End Week on Negative Note -- Market Talk

16.05.2025 г., 18:35 ч. UTC

Топ новини

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 3rd Update

16.05.2025 г., 18:32 ч. UTC

Топ новини

Trump Floats Plan to Impose New Tariff Rates; Stocks Hold Steady -- WSJ

16.05.2025 г., 18:28 ч. UTC

Пазарно говорене

Weaker Dollar Seen as Helping Some Business to Avoid Price Increases -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Celldex Therapeutics Inc Прогноза

Ценова цел

By TipRanks

197.41% нагоре

12-месечна прогноза

Среден 59.78 USD 197.41%

Висок 80 USD

Нисък 36 USD

Според 10 анализатори от Wall Street, предложили 12-месечна ценова цел за Celldex Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

10 ratings

Купи

Задържане

Продай

Според 10 анализатори, дали борсови рейтинги на Celldex Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

18.91 / 20.63Подкрепа & съпротива

Recent bullish events outweigh bearish events.

All events are bearish.

Настроение

By Acuity

173 / 382 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.